Back to search

Democritus University of Thrace (DUTH)

In vivo and in vitro generation of tumor antigen-specific T cells using human CD34+ hematopoietic stem cells or engineered mature T cells

Abstract

dc:description

The last few decades have seen an incredible boost in cancer research that has transformed the clinical reality. However, many patients still do not benefit from current clinical protocols. Can-cer immunotherapy that aims to engage the patient’s immune system in the fight against the dis-ease has emerged as a powerful supplement to standard-of-care treatments. Adoptive cell trans-fer (ACT) lies in the heart of cellular immunotherapies and involves the isolation, expansion, and rejuvenation of a patient’s T cells before reinfusion. Still, reintroduced T cells suffer from poor in vivo persistence and activity, whereas the highly immunosuppressive, adaptive micro-environment, especially of solid cancers, poses an obstacle to ACT’s success. Macrophages, which make up the majority of intratumoral immune cells and are a significant component of the tumor microenvironment (TME), can actively suppress the homing and activity of tumor-specific T cells. Aiming to reprogram the TME and enhance ACT therapies, we describe the generation of tumor-specific ‘armored’ T cells that are further engineered to secrete immuno-modulatory agents. We show that ‘armored’ T cells, producing soluble molecules that block the immunosuppressive cluster of differentiation 47 (CD47)/signal-regulatory protein α (SiRPα) ‘don’t eat me’ pathway, enhance the phagocytic capacity of mouse and human macrophages against human solid tumor targets in vitro and improve tumor control by adoptively transferred T cells in vivo. Furthermore, to achieve long-term antitumor immunity and prolong the in vivo potential of cellular therapies, we report the generation of tumor-specific T cells from genetical-ly engineered hematopoietic stem cells (HSCs) and explore the potential of the generated T cell progenitors in ACT therapy. Thus, our work expands upon established ACT-based methodol-ogies and introduces new cellular products with superior immunomodulatory, tumor-killing properties that can reshape the suppressive cancer microenvironment and mount effective anti-tumor immune responses.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Stefanidis, Evangelos-Nektarios
  • Στεφανίδης, Ευάγγελος-Νεκτάριος

Subjects

dc:subject × 22

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52979

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Stefanidis, Evangelos-Nektarios; Στεφανίδης, Ευάγγελος-Νεκτάριος. In vivo and in vitro generation of tumor antigen-specific T cells using human CD34+ hematopoietic stem cells or engineered mature T cells. Democritus University of Thrace (DUTH), 2022. http://hdl.handle.net/10442/hedi/52979